Cardiometabolic digital diagnostics firm Nanowear introduced a licensing and information partnership with glucose monitoring specialist Dexcom to combine glucose information from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.
Nanowear affords home-based, AI-enabled digital diagnostics for cardiometabolic well being. The corporate’s FDA-cleared SimpleSense wearable reads affected person vitals, equivalent to respiration charge, coronary heart charge, blood strain, bodily exercise, lung quantity and extra.
It makes use of cloth-based nanosensor expertise to seize greater than 120 million information factors each day. The platform then makes use of AI to research the information after which generate experiences for physicians on the information gathered.
Dexcom G7 is an FDA-cleared steady glucose monitoring system worn on the again of the higher arm or higher buttocks that can be utilized by individuals with all kinds of diabetes ages two and up. The wearable monitor measures blood sugar ranges and sends glucose readings to a smartphone or app each 5 minutes.
By the partnership, Nanowear will ingest glucose information from Dexcom G7’s steady glucose monitoring system alongside Nanowear’s cardiovascular biomarkers, which the corporate says will enable medical researchers to acquire real-world and real-time cardiometabolic diagnostic assessments.
“The promise of digital well being over a decade in the past was precision drugs and individualized care that will save sufferers, suppliers and payers money and time whereas selling higher outcomes and expertise,” Venk Varadan, CEO and cofounder of Nanowear, advised MobiHealthNews in an electronic mail.
“Gen 1 and Gen 2 options, whereas profitable in constructing consciousness, by no means really achieved this purpose holistically and diagnostically. With the ability to passively quantify the connection by way of AI between glucose tolerance/insulin sensitivity and hypertension, arrhythmia, sleep apnea, coronary heart failure, and so forth., goes to be a confirmed cardiometabolic answer in precision drugs and individualized care — and Nanowear can now do this.”
THE LARGER TREND
Nanowear obtained FDA clearance for its AI-enabled SimpleSense-BP and SimpleSense-BP Software program Utility in December 2023.
In 2021, the corporate obtained software-only FDA 510(ok) clearance, enabling it to implement standalone AI and deep studying algorithms to tell distant diagnoses as Software program-as-a-Medical Gadget in forthcoming AI-based diagnostics in a closed-loop hospital-at-home community.
In November, Dexcom introduced it made a $75 million strategic funding in health-tracking ring maker Oura, bringing its valuation to greater than $5 billion. The businesses additionally introduced a strategic partnership to allow two-way information movement between Dexcom’s CGM and the Oura Ring.
Dexcom additionally introduced it expanded its diabetes-management capabilities by providing direct connectivity to the Apple Watch for its G7 steady glucose monitoring system by way of a devoted Bluetooth connection.
The glucose monitoring firm secured FDA clearance for its over-the-counter CGM software, Stelo. The gadget is on the market with out requiring a prescription, and the wearable biosensor boasts a battery lifetime of as much as two weeks and adheres to the again of the higher arm.
In 2023, Dexcom introduced a partnership with digital power situation administration platform DarioHealth to permit Dario’s digital well being instruments for metabolic well being to incorporate information from Dexcom CGMs.
